ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License

ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients, according to a company news release.

“Our team is excited to begin serving our home state of California, and its nearly 40 million residents, with high-quality ophthalmic formulations from our FDA-registered 503B outsourcing facility,” John Saharek, President of ImprimisRx, said in a company news release. “We are grateful the state of California has issued this permit, one that has been granted to only a select few of the outsourcing facilities registered with the FDA.”

“The expected impact to ImprimisRx from this new license cannot be understated. While our business as a whole continues to grow nationally, we now expect California demand to significantly pick-up, and for California-specific sales to increase as a percentage of our overall revenue,” Mr. Saharek said. “This California 503B license is coming at a great time as recent investments we’ve made in automated equipment, personnel, and training are expected to increase our production capacity, easily allowing us to absorb the anticipated new demand.”

New or existing ImprimisRx customers interested in placing orders can do so by clicking here.